A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Han, Yang ^a   Lu, Su ^a   Yu, Fudong ^a   Liu, Xisheng ^a   Sun, Huimin ^a   Wang, Jingtao ^a   Zhu, Xingwu ^a   Lu, Huijun ^a   Yue, Hao ^a   Wang, Jing ^a   Lin, Jun ^a   Zhou, Chongzhi ^a   Tang, Huamei ^a   Peng, Zhihai ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADULT; AGED; CANCER STAGING; CLINICAL TRIAL; COLORECTAL TUMOR; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PRECISION MEDICINE;

EID: 84995481716     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep37240     Document Type: Article

References (44)

1. Siegel, R., Desantis, C. & Jemal, A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 64, 104-117, doi: 10.3322/caac.21220 (2014).
2. Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J Clin. 65, 87-108, doi: 10.3322/caac.21262 (2015).
3. Edwards, B. K. et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 116, 544-573, doi: 10.1002/cncr.24760 (2010).
4. Bosetti, C. et al. Recent trends in colorectal cancer mortality in Europe. Int J Cancer. 129, 180-191, doi: 10.1002/ijc.25653 (2011).
5. Gill, S. et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 22, 1797-1806, doi: 10.1200/jco.2004.09.059 (2004).
6. Engstrom, P. F. et al. NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw. 7, 778-831 (2009).
7. Andre, T. et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 27, 3109-3116, doi: 10.1200/jco.2008.20.6771 (2009).
8. Haller, D. G. et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 29, 1465-1471, doi: 10.1200/jco.2010.33.6297 (2011).
9. Kuebler, J. P. et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 25, 2198-2204, doi: 10.1200/jco.2006.08.2974 (2007).
10. (NCCN), N. C. C. N. Clinical Practice Guidelines in Oncology (NCCN Guidelines): Colon Cancer. Version 1.2015, http://www.nccn.org/ (2015).
11. Benson, A. B. 3rd et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 22, 3408-3419, doi: 10.1200/jco.2004.05.063 (2004).
12. Sargent, D. J. et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 345, 1091-1097, doi: 10.1056/NEJMoa010957 (2001).
13. Meester, R. G. et al. Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018. Cancer, doi: 10.1002/cncr.29336 (2015).
14. Douillard, J. Y. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 369, 1023-1034, doi: 10.1056/NEJMoa1305275 (2013).
15. Alberts, S. R. et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. Jama. 307, 1383-1393, doi: 10.1001/jama.2012.385 (2012).
16. Huang, J. et al. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer. 13, 100-109, doi: 10.1016/j.clcc.2013.12.002 (2014).
17. Taieb, J. et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol. 15, 862-873, doi: 10.1016/s1470-2045(14)70227-x (2014).
18. Fornaro, L. et al. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol. 24, 2062-2067, doi: 10.1093/annonc/mdt165 (2013).
19. Harris, T. J. & McCormick, F. The molecular pathology of cancer. Nat Rev Clin Oncol. 7, 251-265, doi: 10.1038/nrclinonc.2010.41 (2010).
20. Cai, H. Y., Caswell, J. L. & Prescott, J. F. Nonculture molecular techniques for diagnosis of bacterial disease in animals: a diagnostic laboratory perspective. Vet Pathol. 51, 341-350, doi: 10.1177/0300985813511132 (2014).
21. Aust, D. E., Sommer, U. & Baretton, G. B. What can molecular pathology offer for optimal decision making? Ann Oncol. 23 Suppl 10, x63-x70, doi: 10.1093/annonc/mds346 (2012).
22. Wang, N., Sun, T., Zheng, R., Zhang, S. & Chen, W. An analysis of incidence and mortality of colorectal cancer in China, 2009. China Cancer. 22, 515-520 (2013).
23. Roth, A. D. et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. Journal of the National Cancer Institute (2012).
24. Wu, C. C., Hsu, T. W., Chang, C. M., Yu, C. H. & Lee, C. C. Age-adjusted Charlson comorbidity index scores as predictor of survival in colorectal cancer patients who underwent surgical resection and chemoradiation. Medicine (Baltimore). 94, e431, doi: 10.1097/md.0000000000000431 (2015).
25. Sanoff, H. K. et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol. 30, 2624-2634, doi: 10.1200/jco.2011.41.1140 (2012).
26. Muss, H. B. & Bynum, D. L. Adjuvant chemotherapy in older patients with stage III colon cancer: an underused lifesaving treatment. J Clin Oncol. 30, 2576-2578, doi: 10.1200/jco.2012.42.3780 (2012).
27. Hanna, N. N. et al. Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: an analysis using surveillance, epidemiology and end results (SEER)-Medicare data. Colorectal Dis. 14, 48-55, doi: 10.1111/j.1463-1318.2011.02545.x (2012).
28. Dotan, E., Browner, I., Hurria, A. & Denlinger, C. Challenges in the management of older patients with colon cancer. J Natl Compr Canc Netw. 10, 213-224, quiz 225 (2012).
29. Dienstmann, R., Salazar, R. & Tabernero, J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol. 33, 1787-1796, doi: 10.1200/jco.2014.60.0213 (2015).
30. Kelley, R. K. & Venook, A. P. Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? Clin Colorectal Cancer. 10, 73-80, doi: 10.1016/j.clcc.2011.03.001 (2011).
31. Maak, M. et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg. 257, 1053-1058, doi: 10.1097/SLA.0b013e31827c1180 (2013).
32. Kennedy, R. D. et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol. 29, 4620-4626, doi: 10.1200/jco.2011.35.4498 (2011).
33. Salazar, R. et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 29, 17-24, doi: 10.1200/jco.2010.30.1077 (2011).
34. Venook, A. P. et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 31, 1775-1781, doi: 10.1200/jco.2012.45.1096 (2013).
35. Gray, R. G. et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 29, 4611-4619, doi: 10.1200/jco.2010.32.8732 (2011).
36. O'Connell, M. J. et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 28, 3937-3944, doi: 10.1200/jco.2010.28.9538 (2010).
37. Reimers, M. S. et al. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients. J Natl Cancer Inst. 106, doi: 10.1093/jnci/dju269 (2014).
38. Gradishar, W. J. et al. Breast Cancer Version 2. 2015. J Natl Compr Canc Netw. 13, 448-475 (2015).
39. Cochrane, D. R. et al. Role of the and rogen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 16, R7, doi: 10.1186/bcr3599 (2014).
40. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 163, 1011-1025, doi: 10.1016/j.cell.2015.10.025 (2015).
41. Linehan, W. M. et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. doi: 10.1056/NEJMoa1505917 (2015).
42. Grieb, B. C., Chen, X. & Eischen, C. M. MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival. Mol Cancer Res. 12, 1216-1224, doi: 10.1158/1541-7786.mcr-14-0069 (2014).
43. Edge, S. B. et al. AJCC cancer staging manual. Vol. 649 (Springer New York, 2010).
44. Han, Y. et al. Overexpression of HOXA10 promotes gastric cancer cells proliferation and HOXA10(+)/CD44(+) is potential prognostic biomarker for gastric cancer. Eur J Cell Biol. 94, 642-652, doi: 10.1016/j.ejcb.2015.08.004 (2015).